Areas of interest (AOI) & competitive research grants
We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
| Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
| Start Date | End date | ||
| Cardiovascular - Mavacamten | 09-May-2025 | 30-May-2025 | 12-Jun-2025 |
Cardiovascular - Mavacamten
• CAMZYOS impact on disease
In Scope:
- Impact of mavacamten on morbidity and quality of life
- Impact on patients with earlier intervention and earlier diagnosis (less symptomatic, milder phenotype)
- Impact of mavacamten on disease or long-term outcome (ie. cardiac structure, underline diseases, risk factors, association between indicators of remodeling and clinical measures)
- Efficacy in patients underrepresented and/or with comorbidities in clinical trials
Out of Scope:
- Head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; Myosin genotyping
- Pediatric populations
- Algorithms and technologies (i.e. Viz-AI, etc.)
- Repeat of BMS clinical trial data
- Post-hoc analysis and/or reanalysis of BMS clinical data
- Studies with biomarker data as primary endpoint
- Off label population (LVEF < 50%, NYHA I and IV)
• Implementation of best practices
In Scope:
- Decision-making support to include patient-preference/patient reported outcomes
- Approaches to workflow optimization and management (quality–improvement studies, improvement of diagnosis)
- Impact on real world clinical use (eg. background meds, transition of care, etc.)
Out of Scope:
- Head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; Myosin genotyping
- Pediatric populations
- Algorithms and technologies (i.e. Viz-AI, etc.)
- Repeat of BMS clinical trial data
- Post-hoc analysis and/or reanalysis of BMS clinical data
- Studies with biomarker data as primary endpoint
- Off label population (LVEF < 50%, NYHA I and IV)
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here